Gina Mauro

Vice President of Content, OncLive and Cancer Network
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Articles

Randall Talks Rich AAOS 2022 Program, Packed With Engaging Discussions

March 28th 2022

R. Lor Randall, MD, discusses takeaways from the American Academy of Orthopaedic Surgeons 2022 Annual Meeting.

Axi-Cel Shows Clinically Meaningful Improvement in QOL in Second-Line Relapsed/Refractory LBCL

March 23rd 2022

Axicabtagene ciloleucel demonstrated a clinically improvement in quality of life compared with standard of care chemotherapy in the second-line setting for patients with relapsed/refractory large B-cell lymphoma.

CD34 Selection Process Evolves into Practice-Changing Approaches in Hematologic Cancers

March 21st 2022

Miguel-Angel Perales, MD, discusses the science behind Orca-T and other approaches targeted to improve GVHD relapse-free survival in select patients with hematologic cancers.

IP Carboplatin/Paclitaxel Improves PFS, But Not OS, Vs IV Chemo in Ovarian Cancer

March 20th 2022

The use of intraperitoneal carboplatin with paclitaxel improved progression-free survival, but not overall survival, vs intravenous chemotherapy in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

FDA Approves Adjuvant Olaparib for BRCA+, High-Risk Early Breast Cancer

March 11th 2022

The FDA has approved olaparib for the adjuvant treatment of patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who have previously received chemotherapy either before or after surgery.

Higher Doses of Ibrutinib/Venetoclax Not Linked With Higher Responses in Relapsed/Refractory MCL

March 8th 2022

The combination of ibrutinib given at 420 mg and venetoclax at 200 mg elicited an objective response rate of 93.8% in patients with relapsed/refractory mantle cell lymphoma, according to results of a phase 1 dose-finding study.

Adjuvant CDK4/6 Inhibitors Demonstrate Success in Early-Stage HR+ Breast Cancer Development

March 4th 2022

CDK4/6 inhibitors in the metastatic setting have demonstrated clinical benefit in the hormone receptor–positive breast cancer population, leading to curiosity of its activity in early-stage patients and setting the stage for a handful of informative clinical trials.

FDA Approves Pacritinib for Intermediate- or High-Risk Myelofibrosis With Severe Thrombocytopenia

March 1st 2022

The FDA has granted an accelerated approval to pacritinib (Vonjo) for the treatment of select adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

FDA Approves Cilta-Cel for Relapsed/Refractory Multiple Myeloma

March 1st 2022

The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed and/or refractory multiple myeloma following 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

ASCO GU 2022: Reflecting on RCC Data With Drs. Toni Choueiri and Peter Van Veldhuizen

February 21st 2022

OncLive® speaks with Drs. Toni Choueiri and Peter Van Veldhuizen on the latest studies in renal cell carcinoma that were presented during the 2022 Genitourinary Cancers Symposium.

ASCO GU 2022: Breaking Down Bladder Cancer Results With Drs. Jonathan Rosenberg and Guru Sonpavde

February 19th 2022

OncLive® speaks with Drs. Jonathan Rosenberg and Guru Sonpavde on the groundbreaking research being presented in bladder cancer.

Frontline Maintenance Avelumab Shows Consistent OS Benefit in Advanced Urothelial Cancer

February 18th 2022

The frontline maintenance combination of avelumab plus best supportive care continued to show an improvement in overall survival compared with BSC alone in patients with metastatic urothelial cancer who receive first-line chemotherapy.

ASCO GU 2022: Piecing Together Prostate Cancer Data With Drs. Tanya Dorff and Jathin Bandari

February 18th 2022

OncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.

Olaparib/Abiraterone Combo Significantly Improves Radiographic PFS in mCRPC

February 17th 2022

Olaparib in combination with abiraterone acetate led to a 34% reduction in the risk of radiographic disease progression or death compared with placebo and abiraterone as a first-line treatment for patients with metastatic castration-resistant prostate cancer, according to results of the phase 3 PROpel trial.

Collaborations With Orthopedic Surgeons, Interventional Radiologists Key to Novel Approaches in Metastatic Bone Cancer

February 15th 2022

R. Lor Randall, MD, discusses the importance of collaborations between orthopedic surgeons and interventional radiologists, and how they are beginning to pick up steam in the United States for patients with metastatic bone cancer.

UCSF Showcases Potentially Game-Changing Trials Across Multiple Myeloma Settings

February 14th 2022

Thomas G. Martin, MD, discusses some of the exciting clinical trials open at UCSF Helen Diller Family Comprehensive Cancer Center in multiple myeloma, especially for those in the relapsed/refractory setting.

Repeat Molecular Testing Is Beneficial in EGFR+ NSCLC With Acquired Resistance

February 7th 2022

Repeat histologic evaluation and molecular testing in patients with EGFR-mutant non–small cell lung cancer who develop acquired resistance to osimertinib can deliver pertinent information that can help guide subsequent treatment decisions.

Orca-T Graft Improves Outcomes in Myelofibrosis Following Allogeneic Stem Cell Transplant

February 4th 2022

Arpita Gandhi, MD, discusses a subgroup analysis of patients with myelofibrosis who received Orca-T and how this type of therapy could be a game-changer for this patient population.

Orca-T Reduces GVHD, Improves GVHD-Free RFS in Posttransplant Setting Across Hematologic Cancers

January 28th 2022

Arpita Gandhi, MD, discusses the background of Orca-T in further detail and how this type of treatment could revolutionize outcomes for patients with serious hematologic malignancies.

Gender, Racial, and Socioeconomic Status Disparities Linked With Incidence of Metastatic Bone Disease

January 26th 2022

R. Lor Randall, MD, speaks to the findings from a report that said multiple sex-related, racial/ethnic, and socioeconomic status disparities are associated with an increased incidence of metastatic bone disease originating from cancers in the prostate, renal, colon, lung, and breast.